Elagolix治疗子宫内膜异位症患者健康相关生活质量的改善
本研究汇总分析了两项Elagolix治疗子宫内膜异位症相关中重度疼痛的III期试验数据,比较安慰剂、Elagolix 150 mg每日一次和200 mg每日两次三组。采用EHP-30问卷评估健康相关生活质量,结果显示Elagolix组在多个维度达到临床有意义改善的概率高于安慰剂组。
要点
- Elagolix 200 mg每日两次组在EHP-30疼痛、控制与无力感、自我形象、社会支持、情绪健康及性交等维度达到应答者定义的概率均显著高于安慰剂组(所有P<.001)。
- Elagolix 150 mg每日一次组除性交维度外,其余各维度达到应答者定义的概率也高于安慰剂组(所有P<.05)。
- Elagolix治疗可使子宫内膜异位症相关中重度疼痛患者获得临床有意义的健康相关生活质量改善。
核心结论
- Elagolix治疗子宫内膜异位症相关中重度疼痛患者可带来临床有意义的健康相关生活质量改善。
研究设计与样本
- 汇总两项Elagolix治疗子宫内膜异位症相关中重度疼痛的III期试验数据,分为安慰剂组、Elagolix 150 mg每日一次组和Elagolix 200 mg每日两次组进行分析。
- 患者在基线及治疗第1、3、6个月时填写EHP-30问卷,采用预先确立的应答者定义判定达到临床有意义改善的比例。
- 采用Poisson回归分析,控制基线评分,比较Elagolix组与安慰剂组在第3和第6个月达到EHP-30应答者定义的概率。
主要发现
- 第6个月时,200 mg组达到EHP-30疼痛、控制与无力感、自我形象、社会支持、情绪健康及性交维度应答者定义的概率分别较安慰剂组高169%(aRR 2.69,95%CI 2.26-3.21)、129%(aRR 2.29,95%CI 1.96-2.67)、80%(aRR 1.80,95%CI 1.54-2.11)、70%(aRR 1.70,95%CI 1.47-1.97)、67%(aRR 1.67,95%CI 1.45-1.92)和62%(aRR 1.62,95%CI 1.36-1.92)(所有P<.001)。
- 150 mg组达到疼痛、控制与无力感、自我形象、社会支持及情绪健康维度应答者定义的概率分别较安慰剂组高75%(aRR 1.75,95%CI 1.44-2.14)、50%(aRR 1.50,95%CI 1.25-1.80)、22%(aRR 1.22,95%CI 1.01-1.47)、30%(aRR 1.30,95%CI 1.09-1.53)和35%(aRR 1.35,95%CI 1.16-1.57)(所有P<.05)。
- 150 mg组在性交维度达到应答者定义的概率未显著高于安慰剂组。
关键数值与推荐
- EHP-30应答者定义基于预先确立的标准判定临床有意义的改善。
- 200 mg组所有维度应答概率均显著高于安慰剂组(所有P<.001)。
- 150 mg组除性交维度外,其余维度应答概率均显著高于安慰剂组(所有P<.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30). METHODS: Data from two phase III trials of elagolix for moderate to severe pain associated with endometriosis were pooled and analyzed as three groups: placebo, elagolix 150 mg once daily, or elagolix 200 mg twice daily. Patients were administered the EHP-30 questionnaire at baseline, and at months 1, 3, and 6 of treatment. Previously established responder definitions were applied to determine percentages of patients with clinically meaningful EHP-30 improvements. The probability of meeting EHP-30 responder definitions with elagolix compared with placebo at months 3 and 6 was determined by Poisson regression analysis, controlling for baseline scores. RESULTS: At month 6, the probabilities of meeting EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, emotional well-being, and sexual intercourse were 169% (adjusted relative risk [aRR]: 2.69, 95% CI 2.26-3.21), 129% (aRR 2.29, 95% CI 1.96-2.67), 80% (aRR 1.80, 95% CI 1.54-2.11), 70% (aRR 1.70, 95% CI 1.47-1.97), 67% (aRR 1.67, 95% CI 1.45-1.92), and 62% (aRR 1.62, 95% CI 1.36-1.92) greater, respectively (all P<.001), in the 200-mg group than in the placebo group. Although lower in magnitude than the 200-mg group, the 150-mg group also had greater probabilities of meeting responder definitions than the placebo group for all subscales except sexual intercourse. The probabilities of meeting responder definitions for pain, control and powerlessness, self-image, social support, and emotional well-being were 75% (aRR 1.75, 95% CI 1.44-2.14), 50% (aRR 1.50, 95% CI 1.25-1.80), 22% (aRR 1.22, 95% CI 1.01-1.47), 30% (aRR 1.30, 95% CI 1.09-1.53), and 35% (aRR 1.35, 95% CI 1.16-1.57) greater, respectively (all P<.05), in the 150-mg group than in the placebo group. CONCLUSION: Patients with moderate to severe pain associated with endometriosis and were treated with elagolix experienced clinically meaningful HRQOL improvements. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01620528 and NCT01931670. FUNDING SOURCE: AbbVie Inc.
引用
- Taylor HS, Soliman AM, Johns B, et al. Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix. Obstet Gynecol. 2020. PMID: 32769633. doi:10.1097/AOG.0000000000003917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。